11:32 AM EDT, 03/13/2024 (MT Newswires) -- PepGen ( PEPG ) said Wednesday that its potential Duchenne muscular dystrophy treatment PGN-EDO51 has received orphan drug and rare pediatric disease designations from the US Food and Drug Administration.

The company said it is currently assessing PGN-EDO51 for the treatment of the muscle-wasting disease in the CONNECT1 phase 2 trial.

The enrollment of patients in the CONNECT2 phase 2 trial is expected to start later this year, the company said.

PepGen ( PEPG ) shares were down 1.4% in recent trading.

Price: 13.66, Change: -0.23, Percent Change: -1.66